Seeking Alpha

BioDelivery +27% AH on positive clinical trial results for pain relief drug

  • BioDelivery Sciences (BDSI) +27.2% AH after the company and Endo Health Solutions (ENDP) announce a late-stage clinical trial for their new chronic pain medication showed significantly improved pain relief.
  • The Phase III trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to a placebo.
  • ENDP +2.4% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs